PDT Partners LLC Acquires 212,250 Shares of Moderna, Inc. $MRNA

Key Points

• PDT Partners LLC significantly increased its holdings in Moderna, Inc. by 3,146.8% during the first quarter, now owning 218,995 shares worth approximately $6.21 million.
• Moderna reported a net loss of ($2.13) earnings per share for the most recent quarter, exceeding analysts' expectations, but its revenue was down 41.1% year-over-year.
• Institutional investors currently hold 75.33% of Moderna's stock, with various firms adjusting their investment positions and ratings in recent months.

PDT Partners LLC increased its position in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 3,146.8% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 218,995 shares of the company's stock after buying an additional 212,250 shares during the period. PDT Partners LLC owned 0.06% of Moderna worth $6,209,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in MRNA. Ameriprise Financial Inc. raised its position in Moderna by 10.8% during the fourth quarter. Ameriprise Financial Inc. now owns 235,280 shares of the company's stock valued at $9,784,000 after acquiring an additional 23,007 shares in the last quarter. BLI Banque de Luxembourg Investments bought a new position in shares of Moderna in the fourth quarter valued at approximately $591,000. Banque Transatlantique SA bought a new position in shares of Moderna in the fourth quarter valued at approximately $2,858,000. Cantor Fitzgerald L. P. acquired a new position in Moderna during the 4th quarter worth $705,000. Finally, Cetera Investment Advisers lifted its position in Moderna by 8.3% during the 4th quarter. Cetera Investment Advisers now owns 40,783 shares of the company's stock worth $1,696,000 after acquiring an additional 3,121 shares during the last quarter. Institutional investors own 75.33% of the company's stock.

Moderna Stock Performance

Shares of NASDAQ MRNA traded up $0.23 during mid-day trading on Thursday, hitting $24.28. 9,148,047 shares of the stock were exchanged, compared to its average volume of 10,734,220. The company has a market cap of $9.45 billion, a P/E ratio of -3.22 and a beta of 1.93. Moderna, Inc. has a twelve month low of $23.15 and a twelve month high of $79.96. The stock's fifty day simple moving average is $28.88 and its two-hundred day simple moving average is $28.63.

Moderna (NASDAQ:MRNA - Get Free Report) last released its quarterly earnings results on Friday, August 1st. The company reported ($2.13) EPS for the quarter, topping analysts' consensus estimates of ($2.99) by $0.86. Moderna had a negative return on equity of 25.96% and a negative net margin of 94.31%.The business had revenue of $142.00 million for the quarter, compared to analyst estimates of $116.26 million. During the same period in the prior year, the company earned ($3.33) EPS. Moderna's revenue for the quarter was down 41.1% on a year-over-year basis. Moderna has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on MRNA. Wells Fargo & Company restated an "equal weight" rating on shares of Moderna in a research note on Sunday, July 13th. Morgan Stanley reiterated an "equal weight" rating and set a $32.00 target price on shares of Moderna in a research note on Friday, August 1st. Leerink Partners decreased their price target on shares of Moderna from $18.00 to $15.00 and set an "underperform" rating on the stock in a research report on Friday, August 22nd. Citigroup began coverage on shares of Moderna in a research report on Friday, August 1st. They set a "neutral" rating and a $40.00 price objective for the company. Finally, William Blair reaffirmed a "market perform" rating on shares of Moderna in a research report on Monday, June 2nd. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, sixteen have assigned a Hold rating and four have given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $42.88.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.